Farag Azza Gaber Antar, Al-Sharaky Dalia Rifaat, Allam Sawsan Samy, Khaled Hesham Nabil
Dermatology, Andrology and STDs Department, Faculty of Medicine, Menoufia University, Shebin ElKom, Egypt.
Pathology Department, Faculty of Medicine, Menoufia University, Shebin ElKom, Egypt.
Clin Cosmet Investig Dermatol. 2020 Jan 10;13:11-19. doi: 10.2147/CCID.S229393. eCollection 2020.
Atopic dermatitis (AD) is a recognized T helper (Th)2, allergic, skin disease. Galectin-9 (gal-9) is a member of galectin family. It alters T-cell balance resulting in Th2 polarization. These Th2 cells yield various cytokines that may influence E selectin expression. Therefore, we hypothesized that gal-9 may have an active role in AD and this role could be mediated through E selectin.
To assess this hypothesis, immunohistochemical expression of gal-9 and E selectin was investigated in skin lesions, from atopic dermatitis patients, and compared.
Twenty-two atopic dermatitis patients and ten controls were included in this case-control study. SCORAD score was used to evaluate atopic dermatitis severity. Biopsies from skin lesions of AD patients and matched sites of controls were taken and stained immunohistochemically by gal-9 and E selectin polyclonal antibodies.
Compared to controls, atopic dermatitis patients exhibited a significant increased gal-9 H score, percent of expression, cellular localization (P˂0.001) and intensity (P=0.04) as well as dermal cellular infiltrate (P˂0.001). Also, there were significant elevations in E selectin H score (P=0.002), percent of expression (P=0.001) and cellular localization (P<0.001) as well as dermal inflammatory infiltrates in AD cases than controls. In AD, 20 cases showed co expression of both gal-9 and E selectin in the epidermis with insignificant correlation between their H scores.
This study only included a small number of studied subjects.
Galectin-9 and E selectin participates independently in atopic dermatitis pathogenesis, that may help in development of new therapeutic agents in atopic dermatitis management program.
特应性皮炎(AD)是一种公认的辅助性T细胞(Th)2型过敏性皮肤病。半乳糖凝集素-9(gal-9)是半乳糖凝集素家族的一员。它会改变T细胞平衡,导致Th2极化。这些Th2细胞产生多种细胞因子,可能影响E选择素的表达。因此,我们推测gal-9可能在AD中发挥积极作用,且这种作用可能通过E选择素介导。
为评估这一假设,研究了特应性皮炎患者皮肤病变中gal-9和E选择素的免疫组化表达并进行比较。
本病例对照研究纳入了22例特应性皮炎患者和10例对照。采用SCORAD评分评估特应性皮炎的严重程度。取AD患者皮肤病变及对照相应部位的活检组织,用gal-9和E选择素多克隆抗体进行免疫组化染色。
与对照组相比,特应性皮炎患者的gal-9 H评分、表达百分比、细胞定位(P<0.001)和强度(P=0.04)以及真皮细胞浸润(P<0.001)均显著增加。此外,AD病例的E选择素H评分(P=0.002)、表达百分比(P=0.001)和细胞定位(P<0.001)以及真皮炎症浸润也显著高于对照组。在AD中,20例患者的表皮中gal-9和E选择素均有共表达,但其H评分之间无显著相关性。
本研究仅纳入了少量研究对象。
半乳糖凝集素-9和E选择素独立参与特应性皮炎的发病机制,这可能有助于开发特应性皮炎治疗方案中的新型治疗药物。